Cyproterone acetate is an effective treatment for women with acne, hair loss, and excessive hair growth.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
49 citations,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
33 citations,
December 2017 in “Journal of neuroendocrinology” Sex and stress steroids quickly change brain cell structures in the hippocampus.
2 citations,
January 1986 in “Dermatology” A woman with Kallman's syndrome also developed alopecia universalis, a condition not previously linked to Kallman's.
34 citations,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
10 citations,
February 2016 in “The Journal for Nurse Practitioners” Healthcare providers need better education and resources to give competent and sensitive care to transgender patients.
February 2024 in “Hormones” Future hormone therapy trials should match the diverse needs and priorities of the gender-diverse community.
March 2023 in “JAAD case reports” 77 citations,
July 2013 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” Menopause reduces skin collagen and elasticity, and while estrogen therapy can help, its risks require careful consideration.
31 citations,
September 2006 in “The Journal of Clinical Endocrinology & Metabolism” Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.
3 citations,
December 2011 in “Pediatric Dermatology” The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.
May 2023 in “Journal of drugs in dermatology” Most transgender patients getting laser hair removal before gender-affirming surgery are already on hormone therapy, which might affect the hair removal process.
146 citations,
December 2016 in “Translational Andrology and Urology” Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.
32 citations,
January 2018 in “American Journal of Clinical Dermatology” Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.
30 citations,
December 2001 in “Journal of The European Academy of Dermatology and Venereology” Hormonal therapy is a good option for women with severe acne, especially when there's a chance of hormone imbalance.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
11 citations,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
1 citations,
July 2011 in “Climacteric” Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.
90 citations,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
6 citations,
January 2016 in “Menopause” Estrogen deficiency, like after menopause or certain surgeries, leads to faster skin aging and health issues.
November 2023 in “International Journal of Women's Dermatology” Hormone replacement therapy may improve hair growth in the frontal hairline of postmenopausal women with hair loss.
104 citations,
January 2005 in “Climacteric” Drospirenone is a unique progestin with anti-water retention and potential blood pressure benefits, used in birth control and hormone therapy.
14 citations,
July 1987 in “Dermatologic Clinics” The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.
2 citations,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
September 1999 in “The Journal of The British Menopause Society” The document concludes that skin aging in women can be caused by UV exposure and hormonal changes, and treatments like hormone replacement therapy and various skin therapies can help.
8 citations,
April 1990 in “Hormone and Metabolic Research” The medication combination did not affect glucose tolerance but increased some cholesterol levels due to its estrogen component.
38 citations,
October 2006 in “Fertility and Sterility” The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.
18 citations,
June 1995 in “International Journal of Dermatology” Women experience various skin issues at different life stages, requiring careful treatment and awareness.
7 citations,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.